• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ligand Reports Second Quarter 2023 Financial Results

    8/8/23 4:01:00 PM ET
    $ALDX
    $GILD
    $JAZZ
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALDX alert in real time by email

    Conference Call Begins at 4:30 p.m. Eastern Time Today

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.

    "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, we are debt free with positive cash flows that can also be deployed. We are well positioned to make additional investments, that, paired with our enhanced deal skillset and expanded team, are expected to add robust programs and diversity to our product pipeline."

    Second Quarter 2023 Financial Results

    Total revenues for the second quarter of 2023 were $26.4 million. Revenues for the same period in 2022 excluding sales related to COVID-19 were $23.9 million. Total revenues for the second quarter of 2022 including COVID-19 related sales were $50.1 million. Royalties for the second quarter of 2023 were $20.4 million, compared with $17.8 million for the same period in 2022, with the increase primarily attributable to Kyprolis, Rylaze and Vaxneuvance. Core Captisol sales were $5.2 million for the second quarter of 2023, compared with $3.3 million for the same period in 2022. The increase in sales was due to the timing of customer orders. There were no Captisol sales related to COVID-19 for the second quarter of 2023, compared with $26.2 million for the same period in 2022. Contract revenue was $0.7 million for the second quarter of 2023, compared with $2.8 million for the same period in 2022. The difference was due to the timing of partner milestone events.

    Cost of Captisol was $1.7 million for the second quarter of 2023, compared with $12.4 million for the same period in 2022, with the decrease due to lower total Captisol sales. Amortization of intangibles was $8.5 million, compared with $8.6 million for the same period in 2022. Research and development expense was $6.9 million, compared with $8.5 million for the same period in 2022, with the decrease attributed to lower stock based compensation, employee related expenses and lab supply expenses. General and administrative expense was $11.3 million, compared with $12.1 million for the same period in 2022, with the decrease primarily attributable to lower legal expenses.

    Net income from continuing operations for the second quarter of 2023 was $2.3 million, or $0.13 per diluted share, compared with net income from continuing operations of $12.6 million, or $0.74 per share, for the same period in 2022. The decrease in net income from the prior year period is due primarily to the decrease in COVID-19 related sales offset by increases in royalty revenue, gain from short term investments and interest income. Adjusted net income from continuing operations for the second quarter of 2023 was $25.1 million, or $1.42 per diluted share, compared with $7.4 million, or $0.43 per diluted share, for the same period in 2022 which excluded the impact of gross profit, net of tax, for Captisol sales related to COVID-19. See the table below for a reconciliation of net income from continuing operations to adjusted net income from continuing operations.

    On May 15, 2023, the 2023 Notes maturity date, we paid off the remaining balance of the convertible notes in amount of $77.1 million (including interest). As of June 30, 2023, Ligand had cash, cash equivalents and short-term investments of $219.0 million. Also in Q2, Ligand put in place a $50 million share repurchase program that expires in April 2026. The timing and amount of repurchase transactions, if any, will be determined by the Company's management based on its evaluation of market conditions, share price, legal requirements and other factors.

    Year-to-Date Financial Results

    Total revenues for the six months ended June 30, 2023 were $70.3 million. Revenues for the same period in 2022 excluding sales related to COVID-19 were $54.5 million. Revenues for the six months ended June 30, 2022 including COVID-19 related sales were $86.6 million. Royalties for the six months ended June 30, 2023 were $37.6 million, compared with $31.3 million for the same period in 2022, with the increase primarily attributable to Kyprolis and the growth in sales of drugs using the Pelican platform. Core Captisol sales were $15.8 million for the six months ended June 30, 2023, compared with $9.6 million for the same period in 2022. The difference in sales was due to the timing of customer orders. There were no Captisol sales related to COVID-19 for the six months ended June 30, 2023, compared with $32.1 million for the same period in 2022. Contract revenue was $16.9 million for the six months ended June 30, 2023, compared with $13.7 million for the same period in 2022. The difference was due to the timing of partner milestone events.

    Cost of Captisol was $5.4 million for the six months ended June 30, 2023, compared with $17.1 million for the same period in 2022, with the decrease due to lower total Captisol sales. Amortization of intangibles was $17.1 million for both the six months ended June 30, 2023 and 2022. Research and development expense for the six months ended June 30, 2023 was $13.5 million, compared with $17.6 million for the same period in 2022, with the decrease attributed to lower employee related expenses and lab supply expenses. General and administrative expense for the six months ended June 30, 2023 was $22.1 million, compared with $24.0 million for the same period in 2022, with the decrease primarily attributable to lower legal expenses.

    Net income from continuing operations for the six months ended June 30, 2023 was $45.9 million, or $2.57 per diluted share, compared with net loss from continuing operations of $0.3 million, or $0.02 per share, for the same period in 2022. The increase in net income was driven by a gain from short term investments of $43.5 million in the current year period and a loss from short term investments of $14.8 million for the same period in 2022. Adjusted net income from continuing operations for the six months ended June 30, 2023 was $65.0 million, or $3.69 per diluted share, compared with $18.4 million, or $1.07 per diluted share, for the same period in 2022 which excluded the impact of gross profit, net of tax, for Captisol sales related to COVID-19. See the table below for a reconciliation of net income (loss) from continuing operations to adjusted net income from continuing operations.

    2023 Financial Guidance

    Ligand is reaffirming its 2023 revenue guidance of $124 million to $128 million and raising adjusted EPS guidance. Guidance for royalties is unchanged at $78 million to $82 million. Sales of Captisol are now expected to be $24 million (previously $21 million) and contract revenue is now expected to be $22 million (previously $25 million). We now expect 2023 adjusted diluted EPS of $4.85 to $5.00 (previously $4.60 to $4.75). The increase in EPS guidance is driven primarily by additional gains realized from the sale of Viking Therapeutics securities. Due to the unpredictable nature of the pandemic and related Captisol sales, Ligand excludes Captisol sales related to COVID-19 from guidance and will update investors as orders are received and shipped each quarter.

    Second Quarter 2023 and Recent Business Highlights

    On July 14, 2023 Ligand made a $3 million bridge loan to Novan, Inc. (NASDAQ:NOVN) in contemplation of Novan filing for bankruptcy relief. On July 17th Novan filed for bankruptcy relief and Ligand entered into an agreement with Novan to purchase its assets for $15 million in cash and provide them up to $15 million in debtor-in-possession financing, inclusive of the $3 million bridge loan. The purchase is subject to approval by the bankruptcy court. Novan's assets include Berdazimer gel, which is in development for molluscum contagiosum infection, and has an NDA with the FDA and an assigned PDUFA goal date of January 5, 2024. If the purchase agreement is approved, and Ligand's bid is successful in the anticipated bankruptcy sale and auction process, Ligand will acquire the Novan assets and consistent with Ligand's business model, will seek to outlicense or sell the existing development programs and commercial business assets of Novan.

    On July 17, 2023 Travere Therapeutics (NASDAQ:TVTX) announced that 417 new patient start forms (PSFs) were received in the second quarter and a total of 563 PSFs have been received since the accelerated approval of FILSPARI was obtained in the first quarter of 2023. Travere also announced the sale of its bile acid product portfolio to Mirum Pharmaceuticals for $210 million upfront and up to $235 million in additional sales based milestones. The sale enables Travere to further focus its efforts on the ongoing launch of FILSPARI for IgA nephropathy and pursing a potential regulatory path forward in FSGS.

    Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its Phase 2b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo. The median relative change from baseline in liver fat as assessed by magnetic resonance imaging, proton density fat fraction (MRI-PDFF) ranged from 38% to 55% for patients receiving VK2809. Additionally, VK2809-treated patients demonstrated statistically significant reductions in low-density lipoprotein cholesterol (LDL-C), triglycerides, and atherogenic lipoproteins compared with placebo.

    Merck (NYSE:MRK) announced its Phase 3 clinical trial of V116, an investigational 21-valent pneumococcal conjugate vaccine, met key immunogenicity and safety endpoints in two Phase 3 trials. If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults. Results from the STRIDE-3 trial demonstrated statistically significant immune responses compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in vaccine-naïve adults for serotypes common to both vaccines. Positive immune responses were also observed for serotypes unique to V116. Additionally, results from STRIDE-6 demonstrated that V116 was immunogenic for all 21 pneumococcal serotypes in the vaccine among adults who previously received a pneumococcal vaccine at least one year prior to the study. In both studies, V116 had a safety profile comparable to the comparator in the studies.

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the European Commission marketing authorization of JZP458 (approved as Rylaze in the U.S.) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.

    Verona Pharma Plc (NASDAQ:VRNA) submitted an NDA to the FDA for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Verona also published results from its Phase 3 ENHANCE trials in the American Journal of Respiratory and Critical Care Medicine demonstrating improvements in lung function, symptoms and quality of life measures, a substantial reduction in the rate and risk of COPD exacerbations and a favorable safety profile.

    Palvella Therapeutics announced a planned pivotal Phase 3 study design of QTORIN rapamycin for the treatment of Microcystic Lymphatic Malformations, following previously announced positive Phase 2 results. Additionally, Palvella announced QTORIN rapamycin did not show a treatment effect when compared to placebo in the pivotal Phase 3 trial in Pachyonychia Congenita and will no longer continue development in that indication.

    Gilead Sciences, Inc. (NASDAQ:GILD) received FDA approval of Veklury (remdesivir) for COVID-19 treatment in patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. The U.S. approval follows the European Commission decision to extend the approved use of Veklury to treat COVID-19 in people with severe renal impairment, including those on dialysis.

    Xintong Pharmaceuticals made an NDA submission of pradefovir for hepatitis B virus (HBV) in China and received Priority Review.

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced positive top-line results from its Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary and all secondary endpoints.

    Adjusted Financial Measures

    Ligand reports adjusted net income and adjusted net income per diluted share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company's financial measures under GAAP include share-based compensation expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based compensation, income tax affect of adjusted reconciling items and others that are listed in the itemized reconciliations between GAAP and adjusted financial measures included at the end of this press release. However, the Company does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, changes in the market value of its investments in public companies, share-based compensation expense and the effects of any discrete income tax items. Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing the Company's past and future core operating performance. Additionally, adjusted earnings per diluted share is a key component of the financial metrics utilized by the Company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation.

    Conference Call

    Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss this announcement and answer questions. To participate via telephone, please dial (888) 350-3452 using the conference ID 6501694. Callers outside the U.S. may dial 1 (646) 960-0369. To participate via live or replay webcast, a link is available at www.ligand.com.

    About Ligand Pharmaceuticals

    Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our platform technologies or both. Our business model generates value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding mid to late-stage drug development in return for economic rights and licensing our technology platforms to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to generate our revenue. We have two primary platform technologies that are available for outlicense – Captisol and Pelican. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. For our Captisol partners, our team supplies the Captisol material needed for their programs. Our Pelican Expression Technology is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.

    About Captisol®

    Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas' Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Gilead Sciences' VEKLURY®, Amgen's KYPROLIS®, Baxter International's NEXTERONE®, Acrotech Biopharma L.L.C.'s and CASI Pharmaceuticals' EVOMELA®, Melinta Therapeutics' BAXDELA™ and Sage Therapeutics' ZULRESSO™. There are many Captisol-enabled products currently in various stages of development. Ligand maintains a broad global patent portfolio for Captisol with approximately 390 issued patents worldwide relating to the technology (including over 40 in the U.S.) and with the latest expiration date in 2033. Other patent applications covering methods of making Captisol, if issued, extend to 2040.

    About the Pelican Expression Technology™ Platform

    Pelican is a validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Multiple global manufacturers have demonstrated consistent success with the platform and the technology is currently out-licensed for numerous commercial and development-stage programs. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. Partners seek the platform as it can contribute significant value to biopharmaceutical development programs by reducing development timelines and costs for manufacturing therapeutics and vaccines. Given pharmaceutical industry trends toward large molecules with increasing structural complexities, Pelican is well positioned to meet these growing needs as one of the most comprehensive broadly available protein production platforms in the industry.

    Follow Ligand on Twitter @Ligand_LGND.

    We use Twitter and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts.

    Forward-Looking Statements

    This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding: the potential to acquire Novan's assets and outlicense or sell its programs and assets; the ability for Travere to focus its efforts on the launch of FILSPARI and pursuing a potential regulatory path forward in FSGS; the timing of clinical and regulatory events of Ligand's partners; the expansion and diversity of Ligand's portfolio; and guidance regarding the full-year 2023 financial results. Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand's business, including, without limitation: Ligand may not receive expected revenue from royalties, Captisol material sales and license fees and milestone revenue; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline; Ligand may not achieve its guidance for 2023; Ligand may not be able to create future revenues and cash flows through its partnerships or otherwise; results of any clinical study may not be timely, favorable or confirmed by later studies; products under development by Ligand or its partners may not receive regulatory approval; the total addressable market for our partners' products may be smaller than estimated; Ligand faces competition with respect to its technology platforms which may demonstrate greater market acceptance or superiority; Ligand is currently dependent on a single source sole supplier for Captisol and failures by such supplier may result in delays or inability to meet the Captisol demands of its partners; there may not be a market for the product(s) even if successfully developed and approved; Ligand's partners may not execute on their sales and marketing plans for marketed products for which Ligand has an economic interest; Ligand's and its partners' products may not be proved to be safe and efficacious and may not perform as expected and uncertainty regarding the commercial performance of such products; Ligand relies on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections; Ligand or its partners may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated; Ligand's partners may terminate any of its agreements or development or commercialization of any of its products; Ligand may not generate expected revenues under its existing license agreements and may experience significant costs as the result of potential delays under its supply agreements; Ligand and its partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Ligand's ability to obtain regulatory approval; unexpected adverse side effects or inadequate therapeutic efficacy of Ligand's or its partners' product(s) could delay or prevent regulatory approval or commercialization; challenges, costs and charges associated with integrating acquisitions with Ligand's existing businesses; Ligand may not be able to acquire, stabilize, outlicense or sell Novan's programs or assets; Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs; restrictions under Ligand's credit agreement may limit its flexibility in operating its business and a default under the agreement could result in a foreclosure of the collateral securing such obligations; pandemics and other epidemic diseases could adversely impact the business of Ligand and its partners and impair global economic activity; changes in general economic conditions, including as a result of the war between Russia and Ukraine; the spin-off of OmniAb may not achieve the intended strategic, operational and financial benefits; and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the company. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional license fees and milestone revenues we may receive. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Other Disclaimers and Trademarks

    The information in this press release regarding certain third-party products and programs, including Kyprolis, an Amgen product, Rylaze, a Jazz Pharmaceuticals product, Pneumosil, a Serum Institute of India product, Berdazimer gel, a Novan product, FILSPARI, a Travere Therapeutics product, QTORIN, a Palvella Therapeutics product, Veklury, a Gilead Sciences product, and other programs described herein, comes from information publicly released by the owners of such products and programs. Ligand is not responsible for, and has no role in, the development of such products or programs.

    Ligand owns or has rights to trademarks and copyrights that it uses in connection with the operation of its business including its corporate name, logos and websites. Other trademarks and copyrights appearing in this press release are the property of their respective owners. The trademarks Ligand owns include Ligand®, Captisol® and Pelican Expression TechnologyTM. Solely for convenience, some of the trademarks and copyrights referred to in this press release are listed without the ®, © and ™ symbols, but Ligand will assert, to the fullest extent under applicable law, its rights to its trademarks and copyrights.

    LIGAND PHARMACEUTICALS INCORPORATED

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Unaudited, in thousands, except per share amounts)

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenues:

     

     

     

     

     

     

     

    Royalties

    $

    20,430

     

     

    $

    17,820

     

     

    $

    37,584

     

     

    $

    31,252

     

    Captisol - Core

     

    5,220

     

     

     

    3,325

     

     

     

    15,842

     

     

     

    9,551

     

    Captisol - COVID

     

    —

     

     

     

    26,220

     

     

     

    —

     

     

     

    32,116

     

    Contract revenue

     

    716

     

     

     

    2,761

     

     

     

    16,919

     

     

     

    13,723

     

    Total revenues

     

    26,366

     

     

     

    50,126

     

     

     

    70,345

     

     

     

    86,642

     

    Operating costs and expenses:

     

     

     

     

     

     

     

    Cost of Captisol

     

    1,669

     

     

     

    12,361

     

     

     

    5,386

     

     

     

    17,060

     

    Amortization of intangibles

     

    8,539

     

     

     

    8,550

     

     

     

    17,078

     

     

     

    17,130

     

    Research and development

     

    6,854

     

     

     

    8,467

     

     

     

    13,517

     

     

     

    17,646

     

    General and administrative

     

    11,287

     

     

     

    12,086

     

     

     

    22,142

     

     

     

    24,011

     

    Total operating costs and expenses

     

    28,349

     

     

     

    41,464

     

     

     

    58,123

     

     

     

    75,847

     

    Income (loss) from operations

     

    (1,983

    )

     

     

    8,662

     

     

     

    12,222

     

     

     

    10,795

     

    Gain (loss) from short-term investments

     

    3,991

     

     

     

    (1,909

    )

     

     

    43,524

     

     

     

    (14,786

    )

    Interest income (expense), net

     

    2,036

     

     

     

    (140

    )

     

     

    3,231

     

     

     

    (795

    )

    Other income, net

     

    (873

    )

     

     

    2,048

     

     

     

    (270

    )

     

     

    4,303

     

    Total other income (expense), net

     

    5,154

     

     

     

    (1

    )

     

     

    46,485

     

     

     

    (11,278

    )

    Income (loss) before income taxes

     

    3,171

     

     

     

    8,661

     

     

     

    58,707

     

     

     

    (483

    )

    Income tax (expense) benefit

     

    (881

    )

     

     

    3,938

     

     

     

    (12,803

    )

     

     

    153

     

    Net income (loss) from continuing operations

     

    2,290

     

     

     

    12,599

     

     

     

    45,904

     

     

     

    (330

    )

    Net loss from discontinued operations

     

    —

     

     

     

    (13,494

    )

     

     

    (1,665

    )

     

     

    (15,950

    )

    Net income (loss):

    $

    2,290

     

     

    $

    (895

    )

     

    $

    44,239

     

     

    $

    (16,280

    )

     

     

     

     

     

     

     

     

    Basic net income (loss) from continuing operations per share

    $

    0.13

     

     

    $

    0.75

     

     

    $

    2.67

     

     

    $

    (0.02

    )

    Basic net loss from discontinued operations per share

    $

    —

     

     

    $

    (0.80

    )

     

    $

    (0.10

    )

     

    $

    (0.95

    )

    Basic net income (loss) per share

    $

    0.13

     

     

    $

    (0.05

    )

     

    $

    2.58

     

     

    $

    (0.97

    )

    Shares used in basic per share calculation

     

    17,276

     

     

     

    16,868

     

     

     

    17,170

     

     

     

    16,846

     

     

     

     

     

     

     

     

     

    Diluted net income (loss) from continuing operations per share

    $

    0.13

     

     

    $

    0.74

     

     

    $

    2.57

     

     

    $

    (0.02

    )

    Diluted net loss from discontinued operations per share

    $

    —

     

     

    $

    (0.79

    )

     

    $

    (0.09

    )

     

    $

    (0.95

    )

    Diluted net income (loss) per share

    $

    0.13

     

     

    $

    (0.05

    )

     

    $

    2.48

     

     

    $

    (0.97

    )

    Shares used in diluted per share calculation

     

    17,730

     

     

     

    17,058

     

     

     

    17,851

     

     

     

    16,846

     

     

     

     

     

     

     

     

     

    LIGAND PHARMACEUTICALS INCORPORATED

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (unaudited, in thousands)

     

     

    June 30, 2023

     

    December 31, 2022

    Assets

     

     

     

    Current assets:

     

     

     

    Cash, cash equivalents and short-term investments

    $

    219,041

     

    $

    211,870

    Accounts receivable, net

     

    27,994

     

     

    30,424

    Inventory

     

    26,906

     

     

    13,294

    Income tax receivable

     

    —

     

     

    4,614

    Other current assets

     

    2,770

     

     

    3,399

    Total current assets

     

    276,711

     

     

    263,601

     

     

     

     

    Deferred income taxes, net

     

    8,530

     

     

    8,530

    Goodwill and other identifiable intangible assets, net

     

    431,050

     

     

    448,128

    Commercial license and other economic rights, net

     

    10,783

     

     

    10,182

    Operating lease right-of-use assets

     

    11,392

     

     

    10,914

    Finance lease

     

    3,762

     

     

    4,095

    Other assets

     

    15,877

     

     

    17,218

    Total assets

    $

    758,105

     

    $

    762,668

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable and accrued liabilities

    $

    16,873

     

    $

    20,988

    Income tax payable

     

    11,387

     

     

    —

    Current operating lease liabilities

     

    680

     

     

    670

    2023 convertible senior notes, net

     

    —

     

     

    76,695

    Other current liabilities

     

    448

     

     

    457

    Total current liabilities

     

    29,388

     

     

    98,810

     

     

     

     

    Long-term contingent liabilities

     

    3,505

     

     

    3,456

    Long-term operating lease liabilities

     

    10,991

     

     

    10,336

    Deferred income taxes, net

     

    27,665

     

     

    30,615

    Other long-term liabilities

     

    21,664

     

     

    21,966

    Total liabilities

     

    93,213

     

     

    165,183

     

     

     

     

    Total stockholders' equity

     

    664,892

     

     

    597,485

    Total liabilities and stockholders' equity

    $

    758,105

     

    $

    762,668

    LIGAND PHARMACEUTICALS INCORPORATED

    ADJUSTED FINANCIAL MEASURES

    (Unaudited, in thousands, except per share amounts)

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

     

     

     

     

     

     

    Net income (loss) from continuing operations

    $

    2,290

     

     

    $

    12,599

     

     

    $

    45,904

     

     

    $

    (330

    )

    Adjustments:

     

     

     

     

     

     

     

    Share-based compensation expense

     

    7,207

     

     

     

    7,001

     

     

     

    13,138

     

     

     

    14,110

     

    Non-cash interest expense (1)

     

    64

     

     

     

    175

     

     

     

    159

     

     

     

    501

     

    Amortization related to acquisitions and intangible assets

     

    8,539

     

     

     

    8,550

     

     

     

    17,078

     

     

     

    17,130

     

    Amortization of commercial license and other economic rights (2)

     

    (508

    )

     

     

    (147

    )

     

     

    (1,001

    )

     

     

    (237

    )

    Change in contingent liabilities (3)

     

    779

     

     

     

    (348

    )

     

     

    108

     

     

     

    (939

    )

    Loss (gain) from short-term investments

     

    (3,991

    )

     

     

    1,909

     

     

     

    (43,524

    )

     

     

    14,786

     

    Realized gain from short-term investments

     

    16,645

     

     

     

    (44

    )

     

     

    37,197

     

     

     

    (288

    )

    Other (4)

     

    94

     

     

     

    (1,700

    )

     

     

    196

     

     

     

    (3,366

    )

    Income tax effect of adjusted reconciling items above

     

    (5,655

    )

     

     

    (8,928

    )

     

     

    (3,675

    )

     

     

    (8,669

    )

    Excess tax benefit from share-based compensation (5)

     

    (353

    )

     

     

    70

     

     

     

    (565

    )

     

     

    87

     

    Adjusted net income from continuing operations

    $

    25,111

     

     

    $

    19,137

     

     

    $

    65,015

     

     

    $

    32,785

     

    Captisol - COVID gross profit, net of tax (6)

     

    —

     

     

     

    (11,763

    )

     

     

    —

     

     

     

    (14,384

    )

    Adjusted net income from continuing operations excluding Captisol - COVID

    $

    25,111

     

     

    $

    7,374

     

     

    $

    65,015

     

     

    $

    18,401

     

     

     

     

     

     

     

     

     

    Diluted per-share amounts attributable to common shareholders:

     

     

     

     

     

     

     

    Diluted net income (loss) per share from continuing operations

    $

    0.13

     

     

    $

    0.74

     

     

    $

    2.57

     

     

    $

    (0.02

    )

    Adjustments:

     

     

     

     

     

     

     

    Share-based compensation expense

     

    0.41

     

     

     

    0.41

     

     

     

    0.75

     

     

     

    0.82

     

    Non-cash interest expense (1)

     

    —

     

     

     

    0.01

     

     

     

    0.01

     

     

     

    0.03

     

    Amortization related to acquisitions and intangible assets

     

    0.48

     

     

     

    0.50

     

     

     

    0.97

     

     

     

    1.00

     

    Amortization of commercial license and other economic rights (2)

     

    (0.03

    )

     

     

    (0.01

    )

     

     

    (0.06

    )

     

     

    (0.01

    )

    Change in contingent liabilities (3)

     

    0.04

     

     

     

    (0.02

    )

     

     

    0.01

     

     

     

    (0.05

    )

    (Gain)/Loss from short-term investments

     

    (0.23

    )

     

     

    0.11

     

     

     

    (2.47

    )

     

     

    0.86

     

    Realized gain from short-term investments

     

    0.94

     

     

     

    —

     

     

     

    2.11

     

     

     

    (0.02

    )

    Other (4)

     

    0.01

     

     

     

    (0.10

    )

     

     

    0.01

     

     

     

    (0.20

    )

    Income tax effect of adjusted reconciling items above

     

    (0.31

    )

     

     

    (0.52

    )

     

     

    (0.22

    )

     

     

    (0.51

    )

    Excess tax benefit from share-based compensation (5)

     

    (0.02

    )

     

     

    —

     

     

     

    (0.03

    )

     

     

    0.01

     

    Adjustment for shares excluded using the if-converted method under ASU 2020-06 (7)

     

    —

     

     

     

    —

     

     

     

    0.04

     

     

     

    —

     

    Adjusted diluted net income per share from continuing operations

    $

    1.42

     

     

    $

    1.12

     

     

    $

    3.69

     

     

    $

    1.91

     

    Captisol - COVID gross profit, net of tax (6)

     

    —

     

     

     

    (0.69

    )

     

     

    —

     

     

     

    (0.84

    )

    Adjusted diluted net income per share from continuing operations excluding Captisol - COVID

    $

    1.42

     

     

    $

    0.43

     

     

    $

    3.69

     

     

    $

    1.07

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    GAAP - weighted average number of common shares - diluted

     

    17,730

     

     

     

    17,058

     

     

     

    17,851

     

     

     

    16,846

     

    Shares excluded due to anti-dilutive effect on GAAP net loss

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    279

     

    Diluted effect of the 2023 Notes (7)

     

    —

     

     

     

    —

     

     

     

    (240

    )

     

     

    —

     

    Adjusted weighted average number of common shares - diluted

     

    17,730

     

     

     

    17,058

     

     

     

    17,611

     

     

     

    17,125

     

    (1)

     

    Amounts represent non-cash debt related costs that are calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

    (2)

     

    Amounts represent the amortization of commercial license and other economic rights to revenue.

    (3)

     

    Amounts represent changes in fair value of contingent consideration related to CyDex and Metabasis transactions.

    (4)

     

    Amounts primarily relate to gain on debt extinguishment and adjustments associated with our equity investment in Nucorion.

    (5)

     

    Excess tax benefits from share-based compensation are recorded as a discrete item within the provision for income taxes on the consolidated statements of operations as a result of the adoption of an accounting pronouncement (ASU 2016-09) on January 1, 2017. Prior to the adoption, the amount was recognized in additional paid-in capital on the consolidated statement of stockholders' equity.

    (6)

     

    Captisol - COVID gross profit, net of tax, represents gross profit, net of tax, for Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.

    (7)

     

    Excluding the impact from the adoption of accounting pronouncement (ASU 2020-06) on January 1, 2022 as the Company intends to settle the principal balance in cash. Under the standard, the Company is required to reflect the dilutive effect of the 2023 Notes by application of the if-converted method, which resulted in an additional 484,463 potentially dilutive shares for the three months ended June 30, 2023, as well as 928,780 and 1,360,030 potentially dilutive shares for the three and six months ended June 30, 2022, respectively.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230808362545/en/

    Get the next $ALDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALDX
    $GILD
    $JAZZ
    $LGND

    CompanyDatePrice TargetRatingAnalyst
    Viking Therapeutics Inc.
    $VKTX
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    Verona Pharma plc
    $VRNA
    4/28/2025$100.00Buy
    TD Cowen
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Gilead Sciences Inc.
    $GILD
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    Verona Pharma plc
    $VRNA
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    Ligand Pharmaceuticals Incorporated
    $LGND
    4/10/2025$143.00Buy
    Stifel
    Viking Therapeutics Inc.
    $VKTX
    4/8/2025$30.00Neutral
    Goldman
    Jazz Pharmaceuticals plc
    $JAZZ
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    More analyst ratings

    $ALDX
    $GILD
    $JAZZ
    $LGND
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto

      Merck Animal Health unveils its largest economic development project in recent history Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health's manufacturing facility in De Soto, Kansas. The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It includes an $860 million investment in the site's existing manufacturing facility and a further $35 million investment in its research and development

      5/8/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Participate at Upcoming Investor Conferences

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare Conference and Jefferies Global Healthcare Conference presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days followi

      5/7/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    $GILD
    $JAZZ
    $LGND
    SEC Filings

    See more
    • Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/8/25 5:26:08 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      5/8/25 7:06:37 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Gilead Sciences Inc.

      10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/7/25 4:32:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALDX
    $GILD
    $JAZZ
    $LGND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00

      4/29/25 8:13:00 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Verona Pharma with a new price target

      TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

      4/28/25 8:38:21 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Merck with a new price target

      Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

      4/22/25 8:01:38 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    $GILD
    $JAZZ
    $LGND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

      4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

      4/8/25 7:05:30 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      4/2/25 6:29:36 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:09:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    $GILD
    $JAZZ
    $LGND
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

      In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

      5/5/25 6:34:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

      5/5/25 4:00:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    $GILD
    $JAZZ
    $LGND
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

      4/17/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components

    $ALDX
    $GILD
    $JAZZ
    $LGND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horning Sandra was granted 1,516 shares, increasing direct ownership by 42% to 5,147 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:26:11 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Manwani Harish covered exercise/tax liability with 296 shares and was granted 1,516 shares, increasing direct ownership by 9% to 14,093 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:18:19 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kramer Kelly A.

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:17:07 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALDX
    $GILD
    $JAZZ
    $LGND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 5:46:11 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 5:13:38 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:50:28 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    $GILD
    $JAZZ
    $LGND
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

      11/15/24 4:36:27 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care